Vanguard Personalized Indexing Management’s Atea Pharmaceuticals AVIR Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$61.7K	Buy	+11,464	New	+$52.6K	﹤0.01%	2023

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vanguard Personalized Indexing Management's AVIR Position: Q1 2026 in Review

Vanguard Personalized Indexing Management opened a new position in Atea Pharmaceuticals (AVIR) in Q1 2026: 11,464 shares worth $61.7K. The stake represents ﹤0.01% of the portfolio and ranks #2023 among its holdings.

127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

Vanguard Personalized Indexing Management held 11,464 shares of Atea Pharmaceuticals worth $61.7K as of Q1 2026.
Atea Pharmaceuticals was a new Vanguard Personalized Indexing Management position in Q1 2026.
Atea Pharmaceuticals made up ﹤0.01% of Vanguard Personalized Indexing Management's portfolio in Q1 2026, its #2023 holding.
127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q1 2026, filed 14 May 2026.